[Immunoscintigraphy of malignant melanoma].
This work is part of a multicentric European evaluation of the monoclonal antibody 225.28s targeted against malignant melanoma and its metastases. Twenty-eight patients (12 males, 16 females, mean age: 53 yrs), who had initially been treated by resection of the primary tumour, were included in the study. Twenty-three of the 26 metastases more than 1 cm in diameter were visualized by immunoscintigraphy. The sensitivity of the procedure (88%) is limited however by the small size of the lesions and their depth, as well as by background noise caused by circulating antibodies. Immunoscintigraphy enables non-invasive investigation of the whole body and can detect lesions that other conventional complementary explorations fail to identify.
Nicol
L
L
Service de Médecine Nucléaire, CHU Rennes, France.
Sandron
A
A
Herry
J Y
JY
Chevrant-Breton
J
J
D000911:Antibodies, Monoclonal; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D006801:Humans; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging; D008545:Melanoma / Q000000981:diagnostic imaging*; D015337:Multicenter Studies as Topic; D011877:Radionuclide Imaging; D012878:Skin Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary
D000911:Antibodies, Monoclonal
Immunoscintigraphie des mélanomes malins.